首页> 外文期刊>Diabetes/metabolism research and reviews >Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats.
【24h】

Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats.

机译:黄ical苷减少链脲佐菌素诱导的糖尿病Wistar大鼠的线粒体损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Hyperglycemia-induced superoxide production in the mitochondria is known to be the primary cause of diabetic micro- and macro-vascular complications and mitochondrial membranal damage. This study in streptozotocin-induced diabetic Wistar rats investigated the anti-hyperglycemic and mitochondrial membrane protection effects of baicalin, a flavonoid known for its radical scavenging activity. METHODS: The following oral treatments were given to diabetic rats for 30 days: (1) metformin 500 mg/kg, (2) baicalin 120 mg/kg, and (3) metformin 500 mg/kg & baicalin 120 mg/kg, with vehicle-treated diabetic and non-diabetic groups serving as controls. RESULTS: Transmission electron microscopy imaging of pancreatic beta-cells revealed loss of integrity of the inner membrane of the mitochondria in the diabetic rats, which was not observed in the baicalin-treated group. In addition, baicalin and the combined treatment of metformin and baicalin had significantly reduced (p < 0.05) the number of mitochondria with a damaged membrane compared to the diabetic control as well as the metformin-treated group in the hepatic tissues. Baicalin had also increased the plasma leptin content (p < 0.05) versus the diabetic control, which in turn had effected the total expression of hepatic mitochondria per cell indicating its effects in SIRT1 activity. The increase in mitochondrial number was further complemented with similar trends in the hepatic citrate synthase activity. CONCLUSIONS: Baicalin had reduced the hyperglycemia-induced mitochondrial membrane damage, as well as enhanced the effects of metformin, as was observed in the results from the metformin and baicalin treated groups.
机译:背景:高血糖诱导的线粒体超氧化物生成是糖尿病微血管和大血管并发症以及线粒体膜质破坏的主要原因。这项在链脲佐菌素诱导的糖尿病Wistar大鼠中的研究研究了黄ical苷(一种以其自由基清除活性而闻名的黄酮类)的抗高血糖和线粒体膜保护作用。方法:对糖尿病大鼠进行以下口服治疗30天:(1)二甲双胍500 mg / kg,(2)黄ical苷120 mg / kg,(3)二甲双胍500 mg / kg和黄kg苷120 mg / kg,媒介物治疗的糖尿病和非糖尿病组作为对照。结果:糖尿病β细胞的透射电镜观察显示,糖尿病大鼠线粒体内膜完整性丧失,黄the苷治疗组未见此现象。此外,与糖尿病对照组以及肝组织中二甲双胍治疗组相比,黄ical苷和二甲双胍与黄ical苷的联合治疗显着减少了膜受损的线粒体数量(p <0.05)。与糖尿病对照组相比,黄ical苷还增加了血浆瘦素含量(p <0.05),进而影响了每个细胞肝线粒体的总表达,表明其对SIRT1活性的影响。线粒体数目的增加与肝柠檬酸合酶活性的类似趋势进一步互补。结论:黄ical苷减少了高血糖引起的线粒体膜损伤,并增强了二甲双胍的作用,如二甲双胍和黄ical素治疗组的结果所示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号